Robert G. L. Shorr
Gründer bei Cornerstone Pharmaceuticals, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Sanjeev Luther | M | 62 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 9 Jahre |
| Uri Yablonka | M | 47 | 10 Jahre | |
| Christofer Toumazou | M | 63 |
Imperial College London
| - |
| Raymond Kurzweil | M | 76 | 22 Jahre | |
| Christopher Patusky | M | 60 | 22 Jahre | |
| Rachel Janis Lomax | F | 78 |
Imperial College London
| 15 Jahre |
| Chaim Lebovits | M | 53 | 17 Jahre | |
| Yael Gothelf | M | - | 17 Jahre | |
| Christopher Causey | M | 61 | 21 Jahre | |
| Alla Patlis | F | 37 | 12 Jahre | |
| Raymond Dwek | M | 82 | 22 Jahre | |
| Howard Jonas | M | 68 |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 11 Jahre |
| Louis Sullivan | M | 90 | 22 Jahre | |
| Robert J. Frey | M | 70 |
Stony Brook University
| - |
| Claudio Albanese | M | 61 |
Imperial College London
| 20 Jahre |
| Michael Gouzman | M | - |
Stony Brook University
| - |
| Andy McKeon | M | 68 |
Imperial College London
| - |
| Elaine Holmes | M | - |
Imperial College London
| - |
| Bill Cleary | M | - |
Stony Brook University
| - |
| Patrick Wilmerding | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Yong Sun Mah | M | 62 |
Imperial College London
| 13 Jahre |
| Judy Murrah | F | 66 |
Stony Brook University
| - |
| Szilard Voros | M | - |
Stony Brook University
| - |
| Hugh Brady | M | 64 |
Imperial College London
| 2 Jahre |
| Charlotte Katherine Williams | F | - |
Imperial College London
| - |
| Aaron Drillick | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Richard Erskine Frere Leakey | M | 79 |
Stony Brook University
| - |
| Lord Darzi | M | 63 |
Imperial College London
| 19 Jahre |
| Samuel L. Stanley | M | - |
Stony Brook University
| 15 Jahre |
| A Joseph Stern | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Hettiaratchy Peter Shehan | M | 55 |
Imperial College London
| - |
| Wing Ching Luk | M | 62 |
Imperial College London
| - |
| Chi Van Dang | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| John Lee Allen | M | - |
Imperial College London
| 4 Jahre |
| Craig Moskowitz | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Manuel London | M | - |
Stony Brook University
| - |
| Eric Cutsem | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Martyn Kingsbury | M | - |
Imperial College London
| - |
| Marsha Pollard | F | - |
Stony Brook University
| - |
| Shawn Heilbron | M | - |
Stony Brook University
| - |
| Mark C. Enright | M | - |
Imperial College London
| 17 Jahre |
| Robert Dickinson | M | - |
Imperial College London
| - |
| Peter Piot | M | 76 |
Imperial College London
| - |
| Stephen R. Bloom | M | - |
Imperial College London
| - |
| Katherine Heaviside | F | 79 |
Stony Brook University
| - |
| Sidney Braginsky | M | 86 |
Stony Brook University
| - |
| John Allan | M | 75 |
Imperial College London
| 4 Jahre |
| Toby Courtauld | M | 56 |
Imperial College London
| - |
| Yair Tauman | M | 65 |
Stony Brook University
| - |
| Rohinton Kalifa | M | 62 |
Imperial College London
| - |
| Alexander P. Hatsis | M | 73 |
Stony Brook University
| - |
| David King | M | 65 |
Stony Brook University
| - |
| Paul Bingham | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Yi Ke Guo | M | 61 |
Imperial College London
| 22 Jahre |
| Sanford Simon | M | 81 |
Stony Brook University
| 55 Jahre |
| Jeffrey S. Yablon | M | - |
Stony Brook University
| - |
| Alice Gast | M | 65 |
Imperial College London
| 10 Jahre |
| I. V. Ramakrishnan | M | - |
Stony Brook University
| - |
| Abderrazzak Merzouki | M | 60 |
Imperial College London
| 17 Jahre |
| David Shrier | M | 49 |
Imperial College London
| 4 Jahre |
| William L. Heaton | M | - |
Stony Brook University
| - |
| Eric Morgan Yeatman | M | 61 |
Imperial College London
| 35 Jahre |
| Edward Bergman | M | - |
Stony Brook University
| - |
| Benjamin Chu | M | - |
Stony Brook University
| - |
| Benjamin S. Hsiao | M | - |
Stony Brook University
| - |
| Zuzana Zachar | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Patrick E. Maloney | M | 68 |
Stony Brook University
| - |
| Clive Zickel | M | - |
Stony Brook University
| - |
| Christopher Levy | M | - |
Stony Brook University
| - |
| Yacov Shamash | M | 74 |
Stony Brook University
| 23 Jahre |
| Michael A. Bender | M | - |
Stony Brook University
| - |
| Daniel R. Ferrara | M | - |
Stony Brook University
| - |
| Shmuel Levinger | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Yoram Drucker | M | 59 | 3 Jahre | |
| Adrian Harel | M | 67 | 2 Jahre | |
| John Maxim Ferrari | M | 69 | 14 Jahre | |
| Ralph Kern | M | 67 | 6 Jahre | |
| Arturo O. Araya | M | 53 | 4 Jahre | |
| Michael Kyriakides | M | - |
Imperial College London
| 7 Jahre |
| Abraham Efrati | M | 74 | 4 Jahre | |
| Abraham Israeli | M | 70 | 4 Jahre | |
| Fumi Kato | M | - |
Stony Brook University
| 8 Jahre |
| Jo Criddle | F | - |
Imperial College London
| 4 Jahre |
| Deji Sasegbon | M | - |
Imperial College London
| 9 Jahre |
| Philippa Christoforou | M | - |
Imperial College London
| 4 Jahre |
| Clea Kolster | F | - |
Imperial College London
| 8 Jahre |
| Aiste Satkute | F | - |
Imperial College London
| 1 Jahre |
| Guan Hua Liu | M | 41 |
Imperial College London
| 4 Jahre |
| Ram Rasaratnam | M | - |
Imperial College London
| 5 Jahre |
| Joshua Lowe | M | - |
Imperial College London
| 4 Jahre |
| Tracy Rice | F | - |
Stony Brook University
| 6 Jahre |
| Adam Karlsson | M | - |
Imperial College London
| 6 Jahre |
| Claire Vassie | F | - |
Imperial College London
| 6 Jahre |
| Martin Knight | M | 74 |
Imperial College London
| 18 Jahre |
| Xu Dong Ren | M | 40 |
Imperial College London
| 5 Jahre |
| Elisa Petris | M | 45 |
Imperial College London
| 7 Jahre |
| Hemali Nisansala Hemachandra | F | - |
Imperial College London
| 5 Jahre |
| Edward Harper | M | - |
Imperial College London
| 2 Jahre |
| Ruchir Saraswat | M | - |
Imperial College London
| 10 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 57 | 57,58% |
| Vereinigtes Königreich | 42 | 42,42% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Robert G. L. Shorr
- Persönliches Netzwerk